

Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Presents to Pain Medicine and Other Physicians at the University of California San Diego



25 APR 14

SILVER SPRING, MD, April 25, 2014 (GLOBE NEWSWIRE) – Medical Marijuana Sciences, Inc. (MMS), a subsidiary of PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, delivered a "Pain Medicine Grand Rounds" presentation to pain specialists and other physicians at the University of California, San Diego (UCSD) that dealt with the medicinal properties of constituents of Cannabis (marijuana) that are known as cannabinoids.

"Dr. Rabe's presentation underscores the remarkable medicinal properties of constituents of Cannabis while demonstrating the work underway at Medical Marijuana Sciences, including our efforts to develop cancer treatments that combine cannabinoids with PharmaCyte Biotech's Cell-in-a-Box® technology, which we believe will result in unique ways to combat this dreadful disease," said Kenneth L. Waggoner, CEO and President of PharmaCyte Biotech. "The physicians at UCSD have been pioneers in research on the medicinal uses of Cannabis. This was an important opportunity to bring Dr. Rabe's expertise to such an influential forum."

Dr. Rabe's presentation, titled "The Science of Cannabis: Pain, Neuroprotection, Cancer," highlighted aspects of the medicinal use of cannabis that make it particularly useful in the treatment of pain. Dr. Rabe offered research showing that cannabinoid molecules act to relieve pain through at least three unique mechanisms. Further, Dr. Rabe presented research and a U.S. Department of Health and Human Services patent documenting the broad antioxidant and neuroprotective properties of cannabinoids. He also presented research showing that cannabinoid molecules, such as THC (tetrahydrocannabinol) and CBD (cannabidiol), have been shown to slow the growth of tumor cells, slow the spread or metastasis of tumors and have a tumor-preventative effect.

Dr. Rabe provides integrative holistic medical services to patients at his San Diego medical practice, Centric Wellness, and throughout his talk provided case studies and examples of patients who have benefited from the use of Cannabis as medicine.

The event was sponsored by the UCSD Department of Anesthesiology and The San Diego Society of Anesthesiologists and occurred on April 23, 2014, with approximately 30 pain specialty and primary care physicians from the University in attendance. UCSD has been on the forefront of medical cannabis research since the establishment of the Center for Medicinal Cannabis Research in 2000. UCSD physicians embrace an overall integrative approach to medical care.

Medical Marijuana Sciences is currently in pre-clinical studies to harness the anti-cancer properties of cannabinoids using PharmaCyte Biotech's Cell-in-a-Box® live-cell encapsulation technology as a platform. Initial targets for the use of such products are projected to be pancreatic and brain cancers – both very serious and deadly forms of the disease.

About Medical Marijuana Sciences:

Medical Marijuana Sciences, Inc., a wholly owned subsidiary of PharmaCyte Biotech, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.

About PharmaCyte Biotech:

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. PharmaCyte Biotech is also involved in clinical trials related to other aspects of pancreatic and other forms of cancer.

Safe Harbor:

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, that could cause actual results to differ materially from those set forth in the forward-looking statements

include PharmaCyte Biotech's ability to continue as a going concern, delays in clinical trials or flaws or defects regarding its products, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech's intellectual property and PharmaCyte Biotech's continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech and Medical Marijuana Sciences can be found at www.nuvilex.com and www.medicalmarijuanasciences.com. It can also be obtained by contacting Investor Relations.

Contact:

Investor Relations Contacts:
Marlin Molinaro
Marmel Communications, LLC
Phone: 702.434.8692
mmolinarofc@aol.com

Media Contact:

Jules Abraham
JQA Partners, LLC
Phone: 917.885.7378
jabraham@jqapartners.com

Posted in [News](#) Posted by [Kenneth L. Waggoner](#)

Contact Us

PharmaCyte Biotech Inc.
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92653
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com



Latest News

PharmaCyte Biotech CEO Visiting GMP Facility with Cellular Biology Consultant During Production of Pancreatic Cancer Product
[4 days ago](#)

PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
[18 days ago](#)

Subscribe to Our Mailing List

* indicates required

Email Address

First Name

Last Name

Email Format

html

text

Subscribe

To search type and hit enter...